The aims of the Genomics England CLL pilot
Are newer, targeted agents better for the management of untreated CLL than chemoimmunotherapy?
A new prognostic tool for CLL: CLL-IPI
Side-effects of inotuzumab ozogamicin
Predict response to immune checkpoint inhibition in acute myeloid leukemia (AML) using biomarkers
Naval G. Daver